Activation of human invariant natural killer T cells with a thioglycoside analogue of α-galactosylceramide

Clinical Immunology

Volumn 140, Issue 2, 2011, Pages 196-207

  Hogan, Andrew E ^a,b   O'Reilly, Vincent ^a   Dunne, Margaret R ^a,b   Dere, Ravindra T ^c   Zeng, Shijuan G ^a   O'Brien, Cashel ^a   Amu, Sylvie ^a   Fallon, Padraic G ^a   Exley, Mark A ^d   O'Farrelly, Cliona ^e   Zhu, Xiangming ^c   Doherty, Derek G ^a,b  

^a ST JAMES S HOSPITAL   (Ireland)

^b NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^c UNIVERSITY COLLEGE DUBLIN   (Ireland)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

Cytokines; Dendritic cells; Glycolipids; Human; NKT cells

Indexed keywords

1 O (ALPHA GALACTOPYRANOSYL) 2 HEXACOSANOYLAMINO 1,3,4 OCTADECANETRIOL; ALPHA GALACTOSYLCERAMIDE; CD1D ANTIGEN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 4; THIOGLYCOSIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER ADJUVANT THERAPY; CELL MATURATION; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOLYSIS; CYTOTOXICITY; DENDRITIC CELL; DRUG BINDING; DRUG EFFICACY; DRUG POTENCY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INVARIANT NATURAL KILLER T CELL; MOUSE; NATURAL KILLER T CELL; NONHUMAN; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TARGET CELL;

ANIMALS; ANTIGEN-PRESENTING CELLS; ANTIGENS, CD1D; CELL LINE; CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GALACTOSYLCERAMIDES; HELA CELLS; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-12; INTERLEUKIN-4; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; MOLECULAR STRUCTURE; NATURAL KILLER T-CELLS; THIOGALACTOSIDES; THIOGLYCOSIDES;

EID: 79960437403     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2011.03.016     Document Type: Article

References (54)

1. Brigl M., Brenner M.B. CD1: antigen presentation and T cell function. Annu. Rev. Immunol. 2004, 22:817-890.
2. Bendelac A., Savage P.B., Teyton L. The biology of NKT cells. Annu. Rev. Immunol. 2007, 25:297-336.
3. Zhou D., Mattner J., Cantu C., Schrantz N., Yin N., Gao Y., Sagiv Y., Hudspeth K., Wu Y.P., Yamashita T., Teneberg S., Wang D., Proia R.L., Levery S.B., Savage P.B., Teyton L., Bendelac A. Lysosomal glycosphingolipid recognition by NKT cells. Science 2004, 306:1786-1789.
4. Kinjo Y., Wu D., Kim G., Xing G.W., Poles M.A., Ho D.D., Tsuji M., Kawahara K., Wong C.H., Kronenberg M. Recognition of bacterial glycosphingolipids by natural killer T cells. Nature 2005, 434:520-525.
5. Kawano T., Cui J., Koezuka Y., Toura I., Kaneko Y., Motoki K., Ueno H., Nakagawa R., Sato H., Kondo E., Koseki H., Taniguchi M. CD1d-restricted and TCR-mediated activation of Vα14 NKT cells by glycosylceramides. Science 1997, 278:1626-1629.
6. Metelitsa L.S., Naidenko O.V., Kant A., Wu H.W., Loza M.J., Perussia B., Kronenberg M., Seeger R.C. Human NKT cells mediate antitumor cytotoxicity directly by recognizing target cell CD1d with bound ligand or indirectly by producing IL-2 to activate NK cells. J. Immunol. 2001, 167:3114-3122.
7. - T cells. J. Exp. Med. 1997, 186:109-120.
8. Gumperz J.E., Miyake S., Yamamura T., Brenner M.B. Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining. J. Exp. Med. 2002, 195:625-636.
9. Kitamura H., Iwakabe K., Yahata T., Nishimura S., Ohta A., Ohmi Y., Sato M., Takeda K., Okumura K., Van Kaer L., Kawano T., Taniguchi M., Nishimura T. T, The natural killer T (NKT) cell ligand α-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells. J. Exp. Med. 1999, 189:1121-1128.
10. Vincent M.S., Leslie D.S., Gumperz J.E., Xiong X., Grant E.P., Brenner M.B. CD1-dependent dendritic cell instruction. Nat. Immunol. 2002, 3:1163-1168.
11. + natural killer T cells mature dendritic cells, leading to strong adaptive immunity. Immunol. Rev. 2007, 220(220):183-198.
12. Liu T.Y., Uemura Y., Suzuki M., Narita Y., Hirata S., Ohyama H., Ishihara O., Matsushita S. Distinct subsets of human invariant NKT cells differentially regulate T helper responses via dendritic cells. Eur. J. Immunol. 2008, 38:1012-1023.
13. Galli G., Nuti S., Tavarini S., Galli-Stampino L., De Lalla C., Casorati G., Dellabona P., Abrignani S. S, CD1d-restricted help to B cells by human invariant natural killer T lymphocytes. J. Exp. Med. 2003, 197:1051-1057.
14. Leadbetter E.A., Brigl M., Illarionov P., Cohen N., Luteran M.C., Pillai S., Besra G.S., Brenner M.B. NK T cells provide lipid antigen-specific cognate help for B cells. Proc. Natl Acad. Sci. U.S.A. 2008, 105:8339-8344.
15. Cui J., Shin T., Kawano T., Sato H., Kond E., Toura I., Kaneko Y., Koseki H., Kanno M., Taniguchi M. Requirement for Vα14 NKT cells in IL-12-mediated rejection of tumors. Science 1997, 278:1623-1626.
16. Hong S., Wilson M.T., Serizawa I., Wu L., Singh N., Naidenko O.V., Miura T., Haba T., Scherer D.C., Wei J., Kronenberg M., Koezuka Y., Van Kaer L. The natural killer T-cell ligand α-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice. Nat. Med. 2001, 7:1052-1056.
17. Crowe N.Y., Coquet J.M., Berzins S.P., Kyparissoudis K., Keating R., Pellicci D.G., Hayakawa Y., Godfrey D.I., Smyth M.J. Differential antitumor immunity mediated by NKT cell subsets in vivo. J. Exp. Med. 2005, 202:1279-1288.
18. Behar S.M., Porcelli S.A. CD1-restricted T cells in host defense to infectious diseases. Curr. Top. Microbiol. Immunol. 2007, 314:215-250.
19. Kenna T., Golden-Mason L., Porcelli S.A., Koezuka Y., Hegarty J.E., O'Farrelly C., Doherty D.G. NKT cells from normal and tumor-bearing human livers are phenotypically and functionally distinct from murine NKT cells. J. Immunol. 2003, 171:1775-1779.
20. + NKT cell numbers are decreased in cancer patients independent of tumor type or tumor load. Int. J. Cancer 2005, 116:87-93.
21. Chang D.H., Osman K., Connolly J., Kukreja A., Krasovsky J., Pack M., Hutchinson A., Geller M., Liu N., Annable R., Shay J., Kirchhoff K., Nishi N., Ando Y., Hayashi K., Hassoun H., Steinman R.M., Dhodapkar M.V. Sustained expansion of NKT cells and antigen-specific T cells after injection of α-galactosyl-ceramide loaded mature dendritic cells in cancer patients. J. Exp. Med. 2005, 201:1503-1517.
22. Motohashi S., Ishikawa A., Ishikawa E., Otsuji M., Iizasa T., Hanaoka H., Shimizu N., Horiguchi S., Okamoto Y., Fujii S., Taniguchi M., Fujisawa T., Nakayama T. A phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non-small cell lung cancer. Clin. Cancer Res. 2006, 12:6079-6086.
23. Terabe M., Swann J., Ambrosino E., Sinha P., Takaku S., Hayakawa Y., Godfrey D.I., Ostrand-Rosenberg S., Smyth M.J., Berzofsky J.A. A nonclassical non-Vα14Jα18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance. J. Exp. Med. 2005, 202:1627-1633.
24. Berzofsky J.A., Terabe M. NKT cells in tumor immunity: opposing subsets define a new immunoregulatory axis. J. Immunol. 2008, 180:3627-3635.
25. Giaccone G., Punt C.J., Ando Y., Ruijter R., Nishi N., Peters M., von Blomberg B.M., Scheper R.J., van der Vliet H.J., van den Eertwegh A.J., Roelvink M., Beijnen J., Zwierzina H., Pinedo H.M. A phase I study of the natural killer T-cell ligand α-galactosylceramide (KRN7000) in patients with solid tumors. Clin. Cancer Res. 2002, 8:3702-3709.
26. Costantino V., D'Esposito M., Fattorusso E., Mangoni A., Basilico N., Parapini S., Taramelli D. Damicoside from Axinella damicornis: the influence of a glycosylated galactose 4-OH group on the immunostimulatory activity of α-galactoglycosphingolipids. J. Med. Chem. 2005, 48:7411-7417.
27. Xing G.W., Wu D., Poles M.A., Horowitz A., Tsuji M., Ho D.D., Wong C.H. Synthesis and human NKT cell stimulating properties of 3-O-sulfo-α/α-galactosylceramides. Bioorg. Med. Chem. 2005, 13:2907-2916.
28. Miyamoto K., Miyake S., Yamamura T. A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells. Nature 2001, 413:531-534.
29. Oki S., Chiba A., Yamamura T., Miyake S. The clinical implication and molecular mechanism of preferential IL-4 production by modified glycolipid-stimulated NKT cells. J. Clin. Invest. 2004, 113:1631-1640.
30. Goff R.D., Gao Y., Mattner J., Zhou D., Yin N., Cantu C., Teyton L., Bendelac A., Savage P.B. Effects of lipid chain lengths in α-galactosylceramides on cytokine release by natural killer T cells. J. Am. Chem. Soc. 2004, 126:13602-13603.
31. Yu K.O., Im J.S., Molano A., Dutronc Y., Illarionov P.A., Forestier C., Fujiwara N., Arias I., Miyake S., Yamamura T., Chang Y.T., Besra G.S., Porcelli S.A. Modulation of CD1d-restricted NKT cell responses by using N-acyl variants of α-galactosylceramides. Proc. Natl Acad. Sci. U.S.A. 2005, 102:3383-3388.
32. Fujio M., Wu D., Garcia-Navarro R., Ho D.D., Tsuji M., Wong C.H. Structure-based discovery of glycolipids for CD1d-mediated NKT cell activation: tuning the adjuvant versus immunosuppression activity. J. Am. Chem. Soc. 2006, 128:9022-9023.
33. Chang Y.J., Huang J.R., Tsai Y.C., Hung J.T., Wu D., Fujio M., Wong C.H., Yu A.L. Potent immune-modulating and anticancer effects of NKT cell stimulatory glycolipids. Proc. Natl Acad. Sci. U.S.A. 2007, 104:10299-10304.
34. Schmieg J., Yang G., Franck R.W., Tsuji M. Superior protection against malaria and melanoma metastases by a C-glycoside analogue of the natural killer T cell ligand α-galactosylceramide. J. Exp. Med. 2003, 198:1631-1641.
35. Silk J.D., Salio M., Reddy B.G., Shepherd D., Gileadi U., Brown J., Masri S.H., Polzella P., Ritter G., Besra G.S., Jones E.Y., Schmidt R.R., Cerundolo V. Cutting edge: nonglycosidic CD1d lipid ligands activate human and murine invariant NKT cells. J. Immunol. 2008, 180:6452-6456.
36. Dere R.T., Zhu X. The first synthesis of a thioglycoside analogue of the immunostimulant KRN7000. Org. Lett. 2008, 10:4641-4644.
37. Rachitskaya A.V., Hansen A.M., Horai R., Li Z., Villasmil R., Luger D., Nussenblatt R.B., Caspi R.R. Cutting edge: NKT cells constitutively express IL-23 receptor and RORγt and rapidly produce IL-17 upon receptor ligation in an IL-6-independent fashion. J. Immunol. 2008, 180:5167-5171.
38. Jiang X., Kojo S., Harada M., Ohkohchi N., Taniguchi M., Seino K.I. Mechanism of NKT cell-mediated transplant tolerance. Am. J. Transplant. 2007, 7:1482-1490.
39. Karadimitris A., Gadola S., Altamirano M., Brown D., Woolfson A., Klenerman P., Chen J.L., Koezuka Y., Roberts I.A., Price D.A., Dusheiko G., Milstein C., Fersht A., Luzzatto L., Cerundolo V. Human CD1d-glycolipid tetramers generated by in vitro oxidative refolding chromatography. Proc. Natl Acad. Sci. U.S.A. 2001, 98:3294-3298.
40. Chiba A., Kaieda S., Oki S., Yamamura T., Miyake S. The involvement of Vα14 natural killer T cells in the pathogenesis of arthritis in murine models. Arthritis Rheum. 2005, 52:1941-1948.
41. Mizuno M., Masumura M., Tomi C., Chiba A., Oki S., Yamamura T., Miyake S. Synthetic glycolipid OCH prevents insulitis and diabetes in NOD mice. J. Autoimmun. 2004, 23:293-300.
42. Ueno Y., Tanaka S., Sumii M., Miyake S., Tazuma S., Taniguchi M., Yamamura T., Chayama K. Single dose of OCH improves mucosal T helper type 1/T helper type 2 cytokine balance and prevents experimental colitis in the presence of Vα14 natural killer T cells in mice. Inflamm. Bowel Dis. 2005, 11:35-41.
43. Forestier C., Takaki T., Molano A., Im J.S., Baine I., Jerud E.S., Illarionov P., Ndonye R., Howell A.R., Santamaria P., Besra G.S., Dilorenzo T.P., Porcelli S.A. Improved outcomes in NOD mice treated with a novel Th2 cytokine-biasing NKT cell activator. J. Immunol. 2007, 178:1415-1425.
44. Li X., Fujio M., Imamura M., Wu D., Vasan S., Wong C.H., Ho D.D., Tsuji M. Design of a potent CD1d-binding NKT cell ligand as a vaccine adjuvant. Proc. Natl Acad. Sci. U.S.A. 2010, 107:13010-13015.
45. Witczak Z.J. Thio sugars: biological relevance as potential new therapeutics. Curr. Med. Chem. 1999, 6:165-178.
46. Zhu X., Schmidt R.R. New principles for glycoside-bond formation. Angew. Chem. Int. Ed Engl. 2009, 48:1900-1934.
47. Lutz M.B., Schuler G. Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunityα. Trends Immunol. 2002, 23:445-449.
48. Blauvelt M.L., Khalili M., Jaung W., Paulsen J., Anderson A.C., Wilson S.B., Howell A.R. α-S-GalCer: synthesis and evaluation for iNKT cell stimulation. Bioorg. Med. Chem. Lett. 2008, 18:6374-6376.
49. Rich J.R., Szpacenko A., Palcic M.M., Bundle D.R. Glycosyltransferase-catalyzed synthesis of thiooligosaccharides. Angew. Chem. Int. Ed Engl. 2004, 43:613-615.
50. Wilson J.C., Kiefel M.J., Angus D.I., von Itzstein M. Investigation of the stability of thiosialosides toward hydrolysis by sialidases using NMR spectroscopy. Org. Lett. 1999, 1:443-446.
51. Kiefel M.J., Thomson R.T., Radocanovi M., von Itzstein M. Synthesis of carbohydrates with an anomeric thiol moiety for elaboration into metabolically stable thioglycosides. J. Carbohydr. Chem. 1999, 18:937-959.
52. MacDougall J.M., Zhang X.D., Polgar W.E., Khroyan T.V., Toll L., Cashman J.R. Design, chemical synthesis, and biological evaluation of thiosaccharide analogues of morphine- and codeine-6-glucuronide. J. Med. Chem. 2004, 47:5809-5815.
53. Witczak Z.J., Culhane J.M. Thiosugars: new perspectives regarding availability and potential biochemical and medicinal applications. Appl. Microbiol. Biotechnol. 2005, 69:237-244.
54. Driguez H. Thiooligosaccharides as tools for structural biology. Chembiochem 2001, 2:311-318.